 |
PDBsum entry 3iqh
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.2.5.1.47
- cysteine synthase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
O-acetyl-L-serine + hydrogen sulfide = L-cysteine + acetate
|
 |
 |
 |
 |
 |
O-acetyl-L-serine
|
+
|
hydrogen sulfide
|
=
|
L-cysteine
Bound ligand (Het Group name = )
matches with 50.00% similarity
|
+
|
acetate
Bound ligand (Het Group name = )
matches with 60.00% similarity
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Cofactor:
|
 |
Pyridoxal 5'-phosphate
|
 |
 |
 |
 |
 |
Pyridoxal 5'-phosphate
Bound ligand (Het Group name =
TYR)
matches with 40.00% similarity
|
|
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
|
J Med Chem
53:345-356
(2010)
|
|
PubMed id:
|
|
|
|
|
| |
|
Design of O-acetylserine sulfhydrylase inhibitors by mimicking nature.
|
|
E.Salsi,
A.S.Bayden,
F.Spyrakis,
A.Amadasi,
B.Campanini,
S.Bettati,
T.Dodatko,
P.Cozzini,
G.E.Kellogg,
P.F.Cook,
S.L.Roderick,
A.Mozzarelli.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The inhibition of cysteine biosynthesis in prokaryotes and protozoa has been
proposed to be relevant for the development of antibiotics. Haemophilus
influenzae O-acetylserine sulfhydrylase (OASS), catalyzing l-cysteine formation,
is inhibited by the insertion of the C-terminal pentapeptide (MNLNI) of serine
acetyltransferase into the active site. Four-hundred MNXXI pentapeptides were
generated in silico, docked into OASS active site using GOLD, and scored with
HINT. The terminal P5 Ile accounts for about 50% of the binding energy. Glu or
Asp at position P4 and, to a lesser extent, at position P3 also significantly
contribute to the binding interaction. The predicted affinity of 14 selected
pentapeptides correlated well with the experimentally determined dissociation
constants. The X-ray structure of three high affinity pentapeptide-OASS
complexes were compared with the docked poses. These results, combined with a
GRID analysis of the active site, allowed us to define a pharmacophoric scaffold
for the design of peptidomimetic inhibitors.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
 |